Skip to main content

A Castegna

First name:
A
Last name:
Castegna
Castegna, A. ., , Klein, J. ., Lynn, B. ., Markesbery, W. ., & Butterfield, D. . (2003). Proteomic identification of nitrated proteins in Alzheimer’s disease brain. Journal of Neurochemistry, 85(6), 1394-401. https://doi.org/10.1046/j.1471-4159.2003.01786.x
Butterfield, D. ., Favia, M. ., Spera, I. ., Campanella, A. ., Lanza, M. ., & Castegna, A. . (2022). Metabolic Features of Brain Function with Relevance to Clinical Features of Alzheimer and Parkinson Diseases. Molecules (Basel, Switzerland), 27(3). https://doi.org/10.3390/molecules27030951 (Original work published 2022)
Palmieri, E. ., Menga, A. ., Lebrun, A. ., Hooper, D. ., Butterfield, D. ., Mazzone, M. ., & Castegna, A. . (2017). Blockade of Glutamine Synthetase Enhances Inflammatory Response in Microglial Cells. Antioxidants & Redox Signaling, 26(8), 351-363. https://doi.org/10.1089/ars.2016.6715 (Original work published 2017)
Butterfield, D. ., Palmieri, E. ., & Castegna, A. . Clinical implications from proteomic studies in neurodegenerative diseases: lessons from mitochondrial proteins. Expert Review of Proteomics, 13(3), 259-74. https://doi.org/10.1586/14789450.2016.1149470 (Original work published 2016)
Butterfield, D. ., Drake, J. ., Pocernich, C. ., & Castegna, A. . (2001). Evidence of oxidative damage in Alzheimer’s disease brain: central role for amyloid beta-peptide. Trends in Molecular Medicine, 7(12), 548-54. https://doi.org/10.1016/s1471-4914(01)02173-6
Castegna, A. ., Aksenov, M. ., Aksenova, M. ., , Klein, J. ., Pierce, W. ., … Butterfield, D. . (2002). Proteomic identification of oxidatively modified proteins in Alzheimer’s disease brain. Part I: creatine kinase BB, glutamine synthase, and ubiquitin carboxy-terminal hydrolase L-1. Free Radical Biology & Medicine, 33(4), 562-71. https://doi.org/10.1016/s0891-5849(02)00914-0 (Original work published 2002)
Butterfield, D. ., Castegna, A. ., Drake, J. ., Scapagnini, G. ., & . (2002). Vitamin E and neurodegenerative disorders associated with oxidative stress. Nutritional Neuroscience, 5(4), 229-39. https://doi.org/10.1080/10284150290028954
Castegna, A. ., Aksenov, M. ., , Klein, J. ., Pierce, W. ., Booze, R. ., … Butterfield, D. . (2002). Proteomic identification of oxidatively modified proteins in Alzheimer’s disease brain. Part II: dihydropyrimidinase-related protein 2, alpha-enolase and heat shock cognate 71. Journal of Neurochemistry, 82(6), 1524-32. https://doi.org/10.1046/j.1471-4159.2002.01103.x
Butterfield, D. ., Castegna, A. ., Lauderback, C. ., & Drake, J. . (1969). Evidence that amyloid beta-peptide-induced lipid peroxidation and its sequelae in Alzheimer’s disease brain contribute to neuronal death. Neurobiology of Aging, 23(5), 655-64. https://doi.org/10.1016/s0197-4580(01)00340-2 (Original work published 1969)
Lauderback, C. ., Drake, J. ., Zhou, D. ., Hackett, J. ., Castegna, A. ., Kanski, J. ., … Butterfield, D. . (2003). Derivatives of xanthic acid are novel antioxidants: application to synaptosomes. Free Radical Research, 37(4), 355-65. https://doi.org/10.1080/1071576021000040664